Latest Industry Insights

A team of multidisciplinary scientists – including bioengineers, materials-scientists and immunologists – at the Wyss Institute has created a novel infection vaccine platform know as OmniVax. Technology Networks spoke with Lead Senior Staff Scientist Ed Doherty from the Wyss Institute for Biologically Inspired Engineering at Harvard University, to learn more.

Up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed a platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.

This article provides tips and tricks for efficient delivery of CRISPR genome editing technology into primary cells and cell lines.

Codexis and Molecular Assemblies recently announced a partnership through which the companies aim to engineer enzymes that will optimize the process of enzymatic DNA synthesis – an alternative approach to chemical DNA synthesis. Technology Networks spoke with Codexis to find out how this will transform the field of DNA synthesis.

Our immune system is incredibly complex. Developing a complete understanding is an enormous undertaking but one to which scientists have been striving in order to advance disease understanding and improve treatments.

Technology Networks recently spoke with David Younger, PhD, Co-founder and CEO of A-Alpha Bio, to learn more about how the company has harnessed synthetic biology and next-generation sequencing techniques to measure millions of interactions between proteins in a single test tube. This enables the identification of potential drugs for the treatment of infectious diseases, including COVID-19.

Earlier this year, researchers reported in Annals of Oncology that they had developed a blood test that was able to detect, with 99.3% specificity, more than 50 types of cancer and identify exactly where in the body the cancer had originated – in some cases before any symptoms of the disease had manifested. We spoke to the study’s corresponding author, Michael V. Seiden MD PhD, to learn more.

The Innovative Genomics Institute (IGI) has launched an impressive COVID-19 diagnostic testing laboratory at UC Berkeley. Technology Networks spoke with Professor Jennifer Doudna, Executive Director at IGI and Professor of Molecular and Cell Biology and Chemistry at the University of California, Berkeley, to learn exactly how this ambitious effort has been achieved.

To learn how clinical metagenomics can be used as a tool to diagnose and understand pathogens such as SARS-CoV-2, Technology Networks recently spoke with Robert Schlaberg, co-founder and CMO of IDbyDNA.

With the first clinical trial of CRISPR gene editing in progress and the controversy of the first gene-edited babies continuing to spark discussion, it is more important than ever to better understand not only the benefits but also the risks of CRISPR-based therapies.